2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 914

The Effects of Vitamin D and Marine Omega-3 Fatty Acid Supplementation on Chronic Knee Pain in Older U.S. Adults
Abstract Number: 915

Development and Initial Validation of the Systemic JADAS, a New Composite Disease Activity Score for Systemic Juvenile Idiopathic Arthritis
Abstract Number: 916

Development and Initial Validation of the MS Score for Diagnosis of Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis
Abstract Number: 917

Systemic Juvenile Idiopathic Arthritis-Lung Disease: Characterization and Risk Factors
Abstract Number: 918

Multiplex Serum Analysis Identifies Potential Biomarkers of Systemic Juvenile Idiopathic Arthritis, Macrophage Activation Syndrome, and Associated Pulmonary Alveolar Proteinosis: Evidence for Independently-regulated Hyperinflammatory and Eosinophilic Inflammation
Abstract Number: 919

Free Interlukin-18: A New Promising Biomarker for Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome
Abstract Number: 920

Adenosine Deaminase 2 as a Circulating Biomarker of Macrophage Activation Syndrome
Abstract Number: 921

Indicators of Actionable Levels of Atherosclerosis in RA Patients Who Appear to Have Low or Intermediate Atherosclerotic Cardiovascular Risk Based on Standard Risk Algorithms
Abstract Number: 922

Improved Incidence of Cardiovascular Disease in Patients with Incident Rheumatoid Arthritis in 2000s: A Population-Based Cohort Study
Abstract Number: 923

First Cardiovascular Event in Rheumatoid Arthritis: Do Patients with Venous Thromboembolism Have a Different Risk Profile Than Patients with Atherosclerotic Cardiovascular Disease?
Abstract Number: 924

Highly-sensitive Cardiac Troponin-I and Beta-2-Glycoprotein-I IgA Antibodies Inform the Utility of Screening and Follow-up Non-invasive Coronary Atherosclerosis Evaluation and Optimize Cardiovascular Risk Assessment in Rheumatoid Arthritis
Abstract Number: 925

Incidence of Dementia and Association with Cardiovascular Disease and Risk Factors in Rheumatoid Arthritis – Analysis of a National Claims Database
Abstract Number: 926

Methotrexate Is Associated with Reduced Cardiovascular Risk in Rheumatoid Arthritis Independent of Disease Activity Modification
Abstract Number: 927

Efficacy and Safety of Filgotinib for Patients with Rheumatoid Arthritis Naïve to Methotrexate Therapy: FINCH3 Primary Outcome Results
Abstract Number: 928

Monotherapy with Upadacitinib in MTX-naïve Patients with Rheumatoid Arthritis: Results at 48 Weeks

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].